Trial Profile
A Pilot Study of Rituximab Neoadjuvant Therapy in Patients With High Risk Prostate Cancer Scheduled to Undergo Radical Prostatectomy
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- 17 May 2017 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
- 17 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
- 17 May 2017 Status changed from recruiting to active, no longer recruiting.